Drug safety evaluation of ziprasidone. - Wikidata - awgldk - TriplyDB

Drug safety evaluation of ziprasidone.

Drug safety evaluation of ziprasidone.

http://www.wikidata.org/entity/Q37844574

about

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.Investigational drugs in recent clinical trials for treatment-resistant depression.Evidence review and clinical guidance for the use of ziprasidone in Canada.Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials.Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.Cardiovascular safety of antipsychotics: a clinical overview.Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats.

P2860

Q30353864-738F6449-632A-49B5-A334-C8AB99004D95 Q33619940-6EC5DB85-279F-4BA9-8304-7B7ADCD2FB6D Q34097289-8C0B13DC-4A50-41A1-8987-318193FB795E Q34226261-76514F8C-400E-46FA-A951-6BA7E95D61CF Q34322714-EA986333-11A9-46CF-9164-EBC90943DC17 Q34549390-82C65817-D843-43DB-90D3-91187BCB1A9D Q36588607-622126CA-D3B1-4FE6-864E-E8BC5ADF49AB Q37933405-E2A3E9A1-E4A2-4212-98A5-32EFF193F96F Q38085441-60BD1651-4A22-48D0-9860-F0248D59FEF4 Q38757870-3F6ACB5B-95DF-48B2-90EC-7A647E5EE0C3 Q48013318-F78F8B83-501C-4C63-87C8-7E4EAD6CA2BC

P2860

Drug safety evaluation of ziprasidone.

http://www.wikidata.org/entity/Q37844574

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drug safety evaluation of ziprasidone.

@en

Drug safety evaluation of ziprasidone.

@nl

type

label

Drug safety evaluation of ziprasidone.

@en

Drug safety evaluation of ziprasidone.

@nl

prefLabel

Drug safety evaluation of ziprasidone.

@en

Drug safety evaluation of ziprasidone.

@nl

P1433

Q37844574-FC9DC58B-3F73-405C-9073-06FB0F6055A7

P1476

Q37844574-327EE13F-FA2F-45D6-946F-041AC2B5A4E3

P2860

Q37844574-000D79E9-CA9B-43C5-8543-AC4E606DD907

Q37844574-013D9F43-FCC7-440E-856C-D0A4D66133F0

Q37844574-0F69C498-6CF2-45D3-BBBC-E174B0AA24AB

Q37844574-1D8EB4A3-17A8-4506-BF13-293CCB7F6BC6

Q37844574-205705D4-6464-4DB9-857E-7DE9B9430D70

Q37844574-2345E24A-5995-4E4E-9B54-C27885AF9319

Q37844574-26E7FC10-FAF9-400B-B619-CD873E8E0346

Q37844574-38208E78-1029-4739-881F-6E4DE1357951

Q37844574-3A611FEC-78B3-46B7-A672-C79F1539BE24

Q37844574-3A8ABD92-2B81-4809-9890-FD5ED1545DF3

P304

Q37844574-202236AD-74F0-486A-B8E7-6E6A3E9D3A0F

P31

Q37844574-57020BEE-A00D-4547-902B-CD0B3935EC4A

P356

Q37844574-CF911EE7-928B-4CF2-8A21-229024B4DFBB

P407

Q37844574-E6A4EB49-70D2-4FFE-9A8E-9A7EF0024367

P433

Q37844574-D5F0C01A-B02B-454C-8DB1-9A7AF52C2CA4

P478

Q37844574-986B523D-0C95-46DB-9A72-EA2DBA5028AE

P50

Q37844574-5305788F-C3B8-43B7-A419-868BEAB6C443

P577

Q37844574-2B97315E-1BCE-4A63-B330-156275ED7877

P698

Q37844574-31BBD8D8-46AA-480B-BE76-662410499D09

P356

14740338.2011.560114

P1433

Expert Opinion on Drug Safety

P1476

Drug safety evaluation of ziprasidone.

@en

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.

Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.

P304

437-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2011.560114

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21332416

http://www.w3.org/2001/XMLSchema#string